Therefore, concomitantly targeting the upstream PI3K/Akt pathway is potentially promising: combining rapamycin with octreotide (a somatostatin analog) more effectively suppresses pituitary tumor cell proliferation than rapamycin alone, with combination treatment proving effective in NFPA cells resistant to single agent rapamycin (114). The gene discussed is PIK3CA; the disease is pituitary tumor.